Get AI Briefings, Transcripts & Alerts on Local & National Government Meetings — Forever.
House Energy and Commerce subcommittee hears competing views on 14 bills to curb illicit drug threats
Loading...
Summary
Lawmakers and experts at a House Energy and Commerce subcommittee hearing debated 14 bills aimed at synthetic opioids and related compounds, with witnesses urging faster forensic reporting and wastewater surveillance while scientists warned blunt scheduling could have unintended clinical and research harms.
The House Energy and Commerce Subcommittee on Health met to review 14 bills targeting illicit synthetic drugs and related enforcement and public‑health measures. Lawmakers opened with competing frames: the majority emphasized scheduling and supply‑side tools to stop deadly counterfeit pills and pill presses, while Democratic members and several witnesses stressed sustaining treatment access and warned that abrupt regulatory changes can harm medical care and research.
The hearing featured a panel that included Scott Olten, a recently retired DEA chief of forensics; Fred Gingrich, DVM, executive director of the American Association of Bovine Practitioners; Dennis Lima, sheriff of Seminole County, Florida; Nabarun Dasgupta, PhD (UNC); and Dr. Ingvold Olson, former director of SAMHSA’s Center for Substance Abuse Treatment. Chair Griffith framed the session as a response to an evolving synthetic‑drug threat and listed bills including HR 1266 (Combating Illicit Xylazine Act), HR 5630 (data collection changes), Tyler’s Law (HR 2004), and several measures aimed at nitazenes, synthetic 7‑OH compounds, and pill‑press controls.
Why it matters: witnesses agreed the drug supply is changing fast and that better, faster data and coordinated responses save lives. They diverged, however, on the central policy tool. Scott Olten told the panel, “The most urgent threat today is counterfeit prescription pills,” arguing that expanded forensic reporting and integration into national databases are essential to detect new compounds rapidly. He advocated wider adoption of DEA’s ‘‘guards’’ approach to capture non‑controlled dangerous compounds and for expanded wastewater testing as an early warning system.
The veterinary community, represented by Dr. Gingrich, urged a statutory scheduling approach that preserves legitimate veterinary access. “Absent congressional action, our understanding is that the DEA will administratively schedule Xylazine,” Gingrich warned; he said administrative scheduling could unintentionally restrict veterinary practice and the drug supply.
Scientists on the panel cautioned that scheduling can have predictable, harmful side effects. Dr. Nabarun Dasgupta described a local substitution pattern after state scheduling—xylazine’s displacement by metatomidine—and said, “If you schedule xylazine and metatomidine, there will be predictable consequences,” including impacts on hospital medicine and research access for important clinical uses.
Members from both parties endorsed a mix of responses: several Republicans urged class‑wide scheduling and tougher controls on pill‑press equipment to blunt rapid chemical tweaks by illicit manufacturers, while Democratic members repeatedly emphasized maintaining treatment access, stable SAMHSA funding and Medicaid protections. Ranking Member DeGette said hearings should prioritize the public‑health approach that helped lower overdose deaths, arguing that “we simply can’t schedule, prosecute, and punish our way out of this.” Dr. Olson warned Congress not to ‘‘move backwards,’’ urging continuation of regulatory changes and investment that expanded treatment access.
Other notable points: law‑enforcement witnesses described seizures of large quantities of fentanyl and multi‑kilogram pill‑press operations; several members pressed the panel on the limits of naloxone where non‑opioid sedatives (xylazine) are involved; witnesses recommended pairing supply‑side laws with investments in forensic capacity, reference materials, and faster data sharing (NIFLIS). Members also discussed the HERO Act to supply naloxone in schools and HR 2715 to give FDA authority to destroy hazardous imports.
The hearing produced no votes. Committee leaders closed by asking witnesses to answer written questions and said members would submit follow‑ups. The subcommittee recessed for recorded votes and later adjourned without marking up the bills.
